Related Experiment Video

Updated: Apr 26, 2026

Use of a Piglet Model for the Study of Anesthetic-induced Developmental Neurotoxicity AIDN: A Translational Neuroscience Approach
06:38

Use of a Piglet Model for the Study of Anesthetic-induced Developmental Neurotoxicity AIDN: A Translational Neuroscience Approach

Published on: June 11, 2017

11.7K

Advances in pediatric pharmacology, therapeutics, and toxicology

Daniel Gonzalez1, Ian M Paul2, Daniel K Benjamin3

  • 1Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, 301 Pharmacy Lane, Chapel Hill, NC 27599, USA; Duke Clinical Research Institute, Duke University Medical Center, 2400 Pratt Street, Durham, NC 27705, USA.

Advances in Pediatrics
|July 20, 2014
PubMed

Insights

US and European regulations now permanently support pediatric clinical trials, increasing the availability of neonatal and pediatric data on drug labels. This ensures safer medication use for younger populations.

Area of Science:

  • Regulatory Science
  • Pediatric Pharmacology
  • Clinical Trial Design

Background:

  • US legislation (FDASIA) made the Best Pharmaceuticals for Children Act (BPCA) and Pediatric Research Equity Act (PREA) permanent.
  • European Pediatric Regulation, effective since 2007, established a framework for pediatric clinical research.
  • Previous regulatory cycles required frequent reauthorization, creating uncertainty for long-term pediatric drug development.

Purpose of the Study:

  • To analyze the impact of recent legislative changes on pediatric clinical research.
  • To assess the increased availability of pediatric data on product labels.
  • To highlight the importance of regulatory frameworks in driving pediatric drug development.

Main Methods:

  • Review of legislative changes in the US (FDASIA, BPCA, PREA) and Europe (Pediatric Regulation).
  • Analysis of trends in pediatric data inclusion on drug product labels.
  • Qualitative assessment of the regulatory landscape's influence on pediatric research.

Main Results:

  • Permanent legislative status for BPCA and PREA in the US removes reauthorization hurdles.
  • The European Pediatric Regulation provides a structured approach to pediatric studies.
  • Increased regulatory guidance has led to more pediatric data being incorporated into drug labels.

Conclusions:

  • Permanent regulatory support enhances the sustainability of pediatric clinical research.
  • European and US regulatory frameworks are crucial for advancing pediatric drug safety and efficacy.
  • Continued focus on regulatory guidance is essential for further expanding pediatric data availability.

Keywords:
PediatricsPharmacokineticsPharmacologyToxicology

More Related Videos

Rapid Evaluation of Toxicity of Chemical Compounds Using Zebrafish Embryos07:49

Rapid Evaluation of Toxicity of Chemical Compounds Using Zebrafish Embryos

Published on: August 25, 2019

10.2K
Author Spotlight: Exploring Venous Waveforms in Porcine Models to Tackle Volume Overload in Medicine06:09

Author Spotlight: Exploring Venous Waveforms in Porcine Models to Tackle Volume Overload in Medicine

Published on: January 12, 2024

1.1K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
405
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
954
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
400
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
547
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
1.0K
Drug Toxicity: Risk factors01:24

Drug Toxicity: Risk factors

Adverse Drug Reactions (ADRs) are potential complications that arise during pharmacotherapy, influenced by multiple risk factors. Age plays a significant role; both neonates and the elderly are at heightened risk due to their respective immature and diminished metabolic and elimination processes. Gender also impacts ADRs, with females experiencing a 1.5 to 1.7-fold greater risk than males, which may be linked to pharmacokinetic, pharmacodynamic, and hormonal differences. Notably, neonates, the...
229